HUE043387T2 - Rák sejt sejt-targetált és gyógyszerrezisztens rákterápia - Google Patents

Rák sejt sejt-targetált és gyógyszerrezisztens rákterápia

Info

Publication number
HUE043387T2
HUE043387T2 HUE10816100A HUE10816100A HUE043387T2 HU E043387 T2 HUE043387 T2 HU E043387T2 HU E10816100 A HUE10816100 A HU E10816100A HU E10816100 A HUE10816100 A HU E10816100A HU E043387 T2 HUE043387 T2 HU E043387T2
Authority
HU
Hungary
Prior art keywords
targeted
stem cell
drug resistant
cancer
cancer therapy
Prior art date
Application number
HUE10816100A
Other languages
English (en)
Inventor
Angelika Burger
Original Assignee
Kominox Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kominox Inc filed Critical Kominox Inc
Publication of HUE043387T2 publication Critical patent/HUE043387T2/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/36Arsenic; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
HUE10816100A 2009-09-10 2010-09-09 Rák sejt sejt-targetált és gyógyszerrezisztens rákterápia HUE043387T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US24118009P 2009-09-10 2009-09-10

Publications (1)

Publication Number Publication Date
HUE043387T2 true HUE043387T2 (hu) 2019-08-28

Family

ID=43647965

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE10816100A HUE043387T2 (hu) 2009-09-10 2010-09-09 Rák sejt sejt-targetált és gyógyszerrezisztens rákterápia

Country Status (24)

Country Link
US (1) US20110059186A1 (hu)
EP (1) EP2475362B1 (hu)
JP (1) JP5710619B2 (hu)
KR (2) KR20120061908A (hu)
CN (2) CN102753164A (hu)
AR (1) AR079000A1 (hu)
AU (1) AU2010292192B2 (hu)
BR (1) BR112012008315B1 (hu)
CA (1) CA2772411C (hu)
CY (1) CY1121973T1 (hu)
DK (1) DK2475362T3 (hu)
ES (1) ES2723778T3 (hu)
HU (1) HUE043387T2 (hu)
IN (1) IN2012DN02008A (hu)
LT (1) LT2475362T (hu)
MX (1) MX2012002855A (hu)
PL (1) PL2475362T3 (hu)
PT (1) PT2475362T (hu)
RU (1) RU2568834C2 (hu)
SG (2) SG179069A1 (hu)
SI (1) SI2475362T1 (hu)
TR (1) TR201905548T4 (hu)
TW (1) TWI564012B (hu)
WO (1) WO2011031890A2 (hu)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1721615A1 (en) 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US20120251628A1 (en) * 2011-03-30 2012-10-04 Young Joo Min Compositions and methods for treatment of cancer
US9963701B2 (en) 2013-09-30 2018-05-08 Korea Institute Of Radiological & Medical Sciences Pharmaceutical composition for treatment of radiation- or drug-resistant cancer comprising HRP-3 inhibitor
WO2017165675A1 (en) * 2016-03-24 2017-09-28 The Board Of Regents Of The University Of Texas System Treatment of drug resistant proliferative diseases with telomerase mediated telomere altering compounds
EP3634494A4 (en) * 2017-05-24 2021-03-17 The Regents of the University of California ANTISENSE THERAPIES TO TREAT CANCER
TWI749414B (zh) * 2019-11-29 2021-12-11 高雄醫學大學 細胞學抹片影像自動分析及診察結果自動批改方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
DE69434093T2 (de) * 1994-02-18 2006-03-09 Tamara Vasilievna Vorobieva Substanz mit immunonodulierender wirkung und zur verringerung der disfunktion des gewebezellenregelungssystems
US5362735A (en) * 1994-02-23 1994-11-08 Smithkline Beecham Corporation Rapamycin derivatives
ATE409043T1 (de) * 1997-10-15 2008-10-15 Polarx Biopharmaceuticals Inc Pharmazeutische zusammensetzungen enthaltend arsentrioxid zur behandlung von krebs des zentralen nervensystems
EP1037625A4 (en) * 1997-11-10 2002-07-31 Sloan Kettering Inst Cancer PROCESS FOR PRODUCING ARSENIC TRIOXIDE FORMULATIONS AND METHODS OF CANCER THERAPY USING ARSENIC TRIOXIDE OR MELARSOPROL
CN1233476A (zh) * 1998-04-24 1999-11-03 陆道培 治疗急性白血病的药物及其制备方法
US6262070B1 (en) * 1998-11-04 2001-07-17 Darwin Discovery Ltd. Heterocyclic compounds and their therapeutic use
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
EP2042182B1 (en) * 2002-04-10 2013-05-22 Komipharm International Co., Ltd. Pharmaceutical composition comprising arsenite for the treatment of malignancy
WO2006104292A1 (en) * 2005-03-31 2006-10-05 Komipharm International Co., Ltd. Pharmaceutical composition comprising arsenic acid, meta-arsenite, and pharmaceutically acceptable salts
EP1721615A1 (en) * 2005-05-09 2006-11-15 Komipharm International Co., Ltd. Pharmaceutical compositions comprising sodium or potassium arsenite for the treatment of urogenital cancer and its metastasis
US20060292243A1 (en) * 2005-06-24 2006-12-28 Shao-Chi Hsin Arsenic compounds for the treatment of the arsenic-sensitive blast-cell related diseases
US8945505B2 (en) * 2007-02-02 2015-02-03 Panaphix, Inc. Use of arsenic compounds for treatment of pain and inflammation
US20080279961A1 (en) * 2007-05-11 2008-11-13 Burger Angelika M Telomere targeting agents as stem cells directed treatments
US20090246291A1 (en) * 2008-03-27 2009-10-01 Angelika Burger Method and compositions for treatment of cancer
BR112012008310A2 (pt) * 2009-09-18 2017-06-06 Kominox Inc métodos para tratamento de tumores cerebrais

Also Published As

Publication number Publication date
AR079000A1 (es) 2011-12-21
IN2012DN02008A (hu) 2015-07-24
LT2475362T (lt) 2019-06-10
EP2475362A4 (en) 2013-03-27
EP2475362A2 (en) 2012-07-18
RU2012108144A (ru) 2013-10-20
EP2475362B1 (en) 2019-03-27
RU2568834C2 (ru) 2015-11-20
BR112012008315A2 (pt) 2016-09-13
PT2475362T (pt) 2019-05-27
CA2772411A1 (en) 2011-03-17
AU2010292192B2 (en) 2015-04-02
KR20120061908A (ko) 2012-06-13
CN107412771A (zh) 2017-12-01
PL2475362T3 (pl) 2019-09-30
JP5710619B2 (ja) 2015-04-30
KR101721009B1 (ko) 2017-03-29
MX2012002855A (es) 2012-07-20
TWI564012B (zh) 2017-01-01
DK2475362T3 (da) 2019-06-03
JP2013504587A (ja) 2013-02-07
US20110059186A1 (en) 2011-03-10
CA2772411C (en) 2017-08-22
TW201114430A (en) 2011-05-01
KR20150038702A (ko) 2015-04-08
CN102753164A (zh) 2012-10-24
SG10201608967WA (en) 2016-12-29
ES2723778T3 (es) 2019-09-02
WO2011031890A2 (en) 2011-03-17
SI2475362T1 (sl) 2019-08-30
WO2011031890A3 (en) 2011-08-25
TR201905548T4 (tr) 2019-05-21
SG179069A1 (en) 2012-04-27
BR112012008315B1 (pt) 2021-08-03
AU2010292192A1 (en) 2012-03-29
WO2011031890A4 (en) 2011-10-13
CY1121973T1 (el) 2020-10-14

Similar Documents

Publication Publication Date Title
EP2740795A4 (en) MEDICAMENT COMPOSITION FOR TREATMENT AND / OR PREVENTION OF CANCER
EP2740798A4 (en) DRUG COMPOSITION FOR CANCER TREATMENT AND / OR PREBUILDING
HK1201724A1 (en) Cancer stem cell-targeted cancer therapy
IL219073A (en) A drug combination for cancer treatment
HK1175476A1 (en) Cancer treatment
PT2582728T (pt) Conjugados fármaco-anticorpo humano contra fator tecidual
EP2531251A4 (en) ADMINISTRATION OF LOCAL THERAPY AND LOCAL ORGAN PROTECTION
ZA201300685B (en) Anticancer derivatives,preparation thereof and therapeutic use thereof
EP2606349A4 (en) AGENTS FOR CANCER DIAGNOSIS AND CANCER THERAPY
GB0922085D0 (en) Cancer diagnosis and treatment
EP2603222A4 (en) COMBINATIVE CANCER TREATMENT
IL219888A0 (en) Pyridine-pyridinone derivatives, preparation and therapeutic use thereof
ZA201201287B (en) Therapeutic aryl-amido-aryl compounds and their use
GB0918392D0 (en) Diagnostic and therapeutic methods
SG10201608967WA (en) Cancer stem cell-targeted and drug resistant cancer therapy
EP2585115A4 (en) ANTICANCER TREATMENT
GB0901837D0 (en) Cancer diagnosis and treatment
GB0905970D0 (en) Depsipeptides and their therapeutic use
EP2473613A4 (en) KREBSAUSHUNGERUNGSTHERAPIE
GB0916997D0 (en) Combination therapy
SI2421864T1 (sl) 1-pirazolo(4,3-c)izokinolinski derivati, njihova priprava in njihova terapevtska uporaba
GB0907973D0 (en) Combination therapy
GB0913603D0 (en) Cancer therapy
GB0921102D0 (en) Cancer Therapy
GB0907098D0 (en) Cancer treatment and diagnosis